EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases.
Charlotte Lm KrieckaertAstrid van TubergenJohanna Elin GehinBorja Hernández-BreijoGuillaume Le MélédoAlejandro BalsaPeter BöhmSasa CucnikOri ElkayamGuro L GollFemke HooijbergMeghna JaniPatrick Dw KielyNeil McCarthyDenis MullemanVictoria Navarro-CompánKatherine PayneMartin E PerryChamaida Plasencia-RodriguezSimon R StonesSilje Watterdal SyversenAnnick de VriesKatherine M WardGertjan WolbinkJohn Dudley IsaacsPublished in: Annals of the rheumatic diseases (2022)
These points-to-consider are evidence-based and consensus-based statements for the use of TDM of biopharmaceuticals in inflammatory RMDs, addressing the clinical utility of TDM.